Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term safety of sNN0029 in ALS
NCT02269436Phase 1Terminated
- Sponsor
- Newron Pharmaceuticals
- Start
- Jan 2015
- Primary completion
- Oct 2015
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 1, open-label, single-arm trial of telbermin in amyotrophic lateral sclerosis (ALS), sponsored by Newron Pharmaceuticals. Primary endpoint: Number of Patients with Adverse Events at 24 Months. Started Jan 2015; status: terminated.
02
Drugs
telbermin
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02269436.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02269436.